More recently, Wiedermann et al. developed a series of B-cell cancer vaccines directed against Her2 or PD-1 with great safety profiles and anti-cancer effects in the animal model [18,19], reiterating that, given a valid target, the active humoral response is suitable for a safe, economic and efficacious cancer therapy [11]. Here, PDCD1 is linked to cancer.